ArticleAmerican journal of preventive cardiology2025
Nonlinear association between glycemic markers and incident cardio‑renal‑metabolic multimorbidity: two decades of follow‑up in the Tehran Lipid and Glucose Study.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between glycemic markers and the incidence of cardio-renal-metabolic multimorbidity (CRMM) in initially disease-free individuals. Methods: We used multivariable Cox proportional hazards models to evaluate associations between fasting plasma glucose (FPG), 2-hour post-load glucose (2hPG), serum insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) with incident CRMM, defined as the coexistence of ≥ 2 of cardiovascular disease (CVD) (including coronary heart disease, stroke, or cardiovascular death), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) among individuals initially free of these conditions. Results: During a median follow-up of 15.3 years (IQR: 11.9-16.4), among 5734 participants (3097 women), 340 (5.9 %) developed CRMM. The most frequent combination among those with incident CRMM was CVD and T2DM (49.1 %), followed by CKD and T2DM (19.7 %), CVD and CKD (18.5 %), and all three conditions (12.6 %). Hazard ratios (HRs) of incident CRMM associated with each 1-standard deviation (SD) increase in FPG, 2hPG, insulin (natural log), and HOMA-IR (natural log) were 1.48 (95 % CI: 1.34-1.64), 1.47 (1.32-1.63), 1.10 (0.91 -1.32), and 1.22 (1.01-1.47), respectively. Prediabetes, defined by either ADA or WHO criteria, was significantly associated with increased CRMM risk. Nonlinear threshold analyses indicated that the risk of CRMM increased significantly above an FPG threshold of 90.92 mg/dL and a 2hPG threshold of 109.92 mg/dL. Conclusions: Glycemic levels below the ADA-defined prediabetes thresholds for both FPG and 2hPG were associated with higher risks of CRMM, suggesting that glucose ranges below the current cut-offs conceal considerable risk and may warrant earlier preventive action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.